A listing on Wegovy getting FDA approval as an obesity treatment, with no date or new details, so likely older news.
Recap by typeshit. Full story at www.polskieradio.pl.
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
A short clip of Rosie O'Donnell discussing the tirzepatide drug Mounjaro. Few details are given beyond the title.
Sam Stone mixed GLP-1 Daily Support powder into a smoothie daily and came away with stomach aches and doubts about what it does.
Dr Desmond Wai shares the Novo Nordisk news and notes the FDA cleared semaglutide for fatty liver disease in the US more than a year earlier.
After advisers backed adding BPC-157, TB-500, KPV and others to the 503A bulks list, pharmacists are waiting on the FDA's final decision.
The claim credits GLP-1 drugs' effects on insulin sensitivity and inflammation for changes in dermatologic conditions. No study is cited.
Loading…